Glasgow-based company betting VLPs can beat biologics on price, dosing and safety for autoimmune and allergic diseases

How the once-dominant cancer company has overhauled its strategy for long-term growth

BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for

Investors don’t like the move, slash $25B from its market cap

Plus: PureTech sells royalty for Karuna’s schizophrenia asset and updates from Dewpoint, Novo Nordisk, Gilead and more

2023 will be a year to digest the upheaval of 2022, and the bar for catalysts has been raised: Reddy on The BioCentury Show

Collaborations between investigators at Asian and Western universities in BioCentury’s Distillery present licensing and partnering opportunities

Plus Ascendis meets in hypoparathyroidism and updates from BridgeBio, AZ, Sanofi, Pfizer and more